Pharmacologic inhibition of the nuclear factor erythroid 2-related factor 2/glutathione pathway via brusatol administration exhibited a potent tumor suppressive effect on IDH1-mutated glioma in vitro and in vivo [18]. This evidence concerns the gene NFE2L2 and central nervous system cancer.